Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.


OBJECTIVE We sought to evaluate the pharmacokinetics of subcutaneously administered enoxaparin sodium during and after pregnancy. STUDY DESIGN Daily subcutaneous injections of enoxaparin sodium (40 mg) were administered to 13 pregnant women. On 3 separate occasions, once early in pregnancy (12-15 weeks), once late in pregnancy (30-33 weeks), and once in… (More)


3 Figures and Tables